Results 21 to 30 of about 742,291 (286)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

The Journal of Clinical Investigation, 2022
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations ...
Zhen Lu, Weiqun Mao, Hailing Yang, Janice M. Santiago-O’Farrill, Philip J. Rask, Jayanta Mondal, Hu Chen, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Yuanxin Xi, Kenta Masuda, Eli M. Carrami, Meng Chen, Yitao Tang, Lan Pang, David S. Lakomy, George A. Calin, Han Liang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr.   +21 more
doaj   +1 more source

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

Journal of Ovarian Research, 2023
As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang, Yu Wang   +4 more
doaj   +1 more source

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil

, 2023
To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March
Angelica Nogueira-Rodrigues, Michelle Samora Almeida, Rachel Cossetti, Karime Kalil, Marcela Crosara, Aknar FC Calabrich, Daniele Xavier Assad, Ana Carolina Leite, Andreia C Melo, Carla Rameri de Azevedo, Andrea PG Guimarães, Alessandra Menezes Morelle, Eduardo Cronemberger, Rodrigo Guindalini, Eduardo Paulino, Graziela Dal-Molin, Daniela de Freitas, João Soares Nunes, Poliana Signorini, Fernando C Maluf, Carla Rameri de-Azevedo, Daniela de-Freitas   +21 more
core   +1 more source

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo

EBioMedicine, 2016
The clinical potential of PARP-1 inhibitors has been recognized >10 years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology.
Colin Thomas, Yingbiao Ji, Niraj Lodhi, Elena Kotova, Aaron Dan Pinnola, Konstantin Golovine, Peter Makhov, Kate Pechenkina, Vladimir Kolenko, Alexei V. Tulin   +9 more
doaj   +1 more source

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data

Frontiers in Pharmacology, 2022
Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have ...
Quanfeng Zhao, Pan Ma, Peishu Fu, Jiayu Wang, Jiayu Wang, Kejing Wang, Kejing Wang, Lin Chen, Lin Chen, Yang Yang, Yang Yang   +10 more
doaj   +1 more source

Hypersensitivity of BRCA1 heterozygote lymphoblastoid cells to gamma radiation and PARP inhibitors [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright @ 2013 Bourton EC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use ...
Bourton, EC, Plowman, PN, Parris, C, Parris, CN, Foster, HA, Harvey, AJ   +5 more
core   +1 more source

PARP inhibitors and more

Journal of the Turkish German Gynecological Association, 2015
Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA) in a cell genome. They are a balancing part of an even more dynamic equilibrium of normalcy against daily assaults.
Chinmoy K, Bose, Nirban, Basu
openaire   +2 more sources

The PARP-1 inhibitor Olaparib causes retention of γ-H2AX foci in BRCA1 heterozygote cells following exposure to gamma radiation [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright © 2013 Emma C. Bourton et al. This is an open access article distributed under the Creative Commons Attribution Li-cense, which permits unrestricted use ...
Bourton, EC, Plowman, PN, Adam Zahir, S, Parris, CN, Harvey, AJ   +4 more
core   +1 more source

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

Frontiers in Oncology, 2021
Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression.
Giacomo Barchiesi, Michela Roberto, Monica Verrico, Patrizia Vici, Silverio Tomao, Federica Tomao, Federica Tomao   +6 more
doaj   +1 more source

PARP Inhibitors in Breast and Ovarian Cancer

, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most ...
Sim Wey Cheng, Heong Valerie Yue Ming, Yeo Ee Jie, Samuel S. Y. Wang, Goh Liuh Ling   +4 more
core   +1 more source